CCC has hosted this seminal pan-cancer clinical trials conference over the last 8 years, uniting clinical trial networks, researchers, industry, academics, trial sponsors, HTA agencies, Health Canada, and national and international cancer patient groups to mention a few.
Over the course of the past several years, we have made considerable progress in fostering patient and patient group partnerships among researchers and stakeholders engaged in cancer clinical trials and their engagement in the clinical trial continuum with a view to increasing access to trials with endpoints that are meaningful to patients.
This year, join us for our 9th Annual Patient-Centered Approach to Clinical Trials Conference where we will explore 'RESEARCH IS CARE AND CARE IS RESEARCH: Unlocking faster innovation for better access, outcomes and hope’.
Patient/Caregiver/Patient Group
Pharmaceutical Company
Contract Research Organization/Clinical Trial Network
Academic Institution
Government Agency/Regulator
Healthcare Professional
Mr. Barry D. Stein, B.Com., B.C.L., LL.B., graduated from McGill University. An accomplished lawyer, he has been a member of the Bar of Quebec since 1981. Barry sits on the Board of Directors of several corporations, not-for-profit organizations and foundations. He is a founding member of the Canadian Partnership Against Cancer National Colorectal Cancer Screening Network. As the president of Colorectal Cancer Canada, Barry represents the interests of cancer patients and speaks regularly to medical professionals, industry, government, and patient groups both in and outside of Canada. Barry has been a key advocate for population-based colorectal cancer screening initiatives, patient and physician education and multidisciplinary health professional consensus guidelines to improve patient outcomes across Canada.
As a survivor of metastatic colorectal cancer diagnosed in 1995, Barry was obliged to seek health care outside of Canada to fight the disease. His judgement, obtained in the Superior Court of Quebec, serves as a leading precedent for the reimbursement of out of country health care.
Stephanie Michaud is the President and CEO of BioCanRx, a not-for-profit organization that seeks to accelerate the delivery of innovative immunotherapies from the bench to the bedside. In this position, Stephanie is responsible for running all facets of the organization. She brings over 20 years of public, government and private sector experience in research and S&T innovation policy. She strives to create partnerships between government, not-for-profits, academia and industry to maximize the impact of research funded by the BioCanRx network on the lives of those affected by cancer. This includes the creations of new opportunities to include the patient voice as equal partner in the BioCanRx research program. Prior to joining BioCanRx, Stephanie was Deputy Director of the flagship Government of Canada Network Centres of Excellence (NCE) program. She is a strong contributor to S&T policy, most notably in intellectual property. Dr. Michaud earned a PhD in Organic Chemistry from McGill University. She is involved with a number of not-for-profit organizations including as Director of the Board of the StemCell Network and Research Canada.
Michael is the Head of Innovation for Hoffmann-La Roche Limited across all of its Canadian divisions, including Roche Pharmaceuticals, Roche Diagnostics, and Roche Diabetes Care. Michael also leads the Roche Innovation Hive – which is the creative space where the future of healthcare is being imagined and co-created between Roche and its external partners. Michael is also a founding board member of the Canadian Personalized Healthcare Innovation Network (CPHIN) which is a not for profit corporation representing a consortium of members from both public and private sectors focused on the acceleration of personalized healthcare for Canada.
Michael received his undergraduate degree in Biology and Pharmacology and a Ph.D. in Medical Sciences with a specialization in Neuroscience, both from McMaster University.
Stephen has over 25 years of experience in clinical trial operations and health programs' leadership. His clinical research expertise includes roles in pharma, CRO and academic settings involving the conduct of Phase 1-3b drug, biologic, and device trials across a wide range of therapeutic areas. The Canadian Cancer Clinical Trials Network (3CTN) maintains a Portfolio of over 800 multi-centre academic cancer clinical trials and mobilizes and supports a pan-Canadian community of over 250 investigators, clinical research professionals and patient partners across its 60 pediatric- and adult-member Cancer Centres in improving shared aims for equitable access, accrual and the efficient, high-quality conduct of trials.
Dr. Rebecca Auer is the Executive Vice-President of Research and Innovation at The Ottawa Hospital and the CEO and Scientific Director of the Ottawa Hospital Research Institute, where she also holds the position of cancer surgeon and Senior Scientist in the Cancer Research Program at the Ottawa Hospital Research Institute (OHRI) and Professor in the Department of Surgery and the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa.
Dr. Auer is an international leader in perioperative cancer therapeutics. She has led six clinical trials of cancer immunotherapies based on preclinical discoveries made in her research lab. She has authored over 100 peer-reviewed publications and received over $30 million dollars in peer-reviewed funding to support her work.
Dr. Auer believes that research IS care and is dedicated to ensuring all patients are provided an opportunity to participate in research. As the co-founder of the Canadian Cholangiocarcinoma Collaborative (C3) which aims provide hope to Canadian patients with biliary tract cancers by integrating research into care. Dr, Auer is a strong advocate for supporting patient engagement and access to research at all levels of government.
Elements Strategy is a strategic management consulting firm providing services to the healthcare industry where transformation through person and patient focused innovation is critical to success. Our core expertise is in leadership and facilitation of planning and innovation initiatives and thought leadership projects including roundtables and conferences. Since 2017, Elements Strategy has been a strategic advisor to Colorectal Cancer Canada. Founded in 1997, Anne Marie Wright has led Elements Strategy in select time periods while also engaged in full time roles as a senior healthcare executive in private, public and not for profit organizations. She has served clients across many sectors including the Pharmaceutical and MedTech industries, Retail Pharmacy, Healthcare Professional Associations and Venture Capital Firms. She works collaboratively and in partnership with many Advisory groups and is a member of the International Association of Facilitators. Today, Elements Strategy also educates and advises organizations on the power of population aging and the new longevity economy. She is an advisor on AGE-WELL NCE’s National Aging Policy and Strategy working group and a member of the Canadian Longitudinal Study on Aging Advisory Council.
Dr Kurt Lackovic is the CEO of Cancer Trials Australia, a position he has held since 2017. Kurt has overseen Cancer Trials Australia’s significant growth, expanding its reach and impact within the Australian clinical trials ecosystem. He has built a career in medical research that spans both academic and commercial settings. Kurt holds a PhD in chemistry, has completed international post-doctoral work in medical genomics and early-stage drug discovery, and earned an MBA from Melbourne Business School. He has published >25 peer-reviewed articles across diverse medical research areas and is a graduate of the Australian Institute of Company Directors. Kurt is also an active member of the American Society of Clinical Oncology, Society for Clinical Research Sites and sits on AusBiotech’s Clinical Trials Advisory Group as well as the Research and Development Task Force. Beyond his role at Cancer Trials Australia, Kurt also serves as a Director for both the Australian Physiotherapy Council and Deadly Science, where he also Chairs their Audit and Risk sub-committees.
Stuart joined the Canadian Cancer Society (CCS) in February 2020 following the amalgamation with Prostate Cancer Canada (PCC). As Executive Vice President of Mission, he oversees the Research and Advocacy teams. Prior to the amalgamation, Stuart spent 8 years at PCC as Vice President of Research, Health Promotion and Survivorship. He has held leadership roles at several national cancer research institutes and government agencies. Stuart holds a Doctorate in pharmacology from Oxford University.
Rebecca began her career as a cancer researcher and, over the past 15 years, has held a range of leadership roles dedicated to strengthening health research capacity within Canada. She specializes in building innovative and sustainable systems that enhance research excellence, while fostering meaningful engagement with diverse interest-holders. Prior to joining N2 Canada, Rebecca played a key role in leading in leading the Canadian Tissue Repository Network and advancing research engagement at Vancouver Island Health Authority, where she managed the CIHR Strategy for Patient-Oriented Research (SPOR) initiative for the Vancouver Island region. Most recently, she served as Director of the Office of the Vice-President Research and Innovation at the University of Victoria. Rebecca holds a Bachelor of Science in Biology and a Master’s degree in Environmental Toxicology/Carcinogenesis.
Allen Chankowsky is an acclaimed author, sought-after international speaker, and a resilient 34-year cancer survivor. His continued survivorship of a 2016 terminal diagnosis of an ultra-rare, Androgen Receptor positive salivary duct carcinoma makes him one of the longest survivors with this disease. Best known for his multi-award-winning & best-selling book, "On the Other Side of TERMINAL," Allen inspires his audience with a powerful narrative of hope and resilience against one of life's gravest challenges. Allen's contributions to the field extend far beyond his personal journey. An expert in sales promotion and marketing, he leverages his platform to actively champion the cause of precision medicine in the diagnosis and treatment of cancer. His compelling insights have earned him keynote invitations to prestigious events, including the TargetCancer Foundation's 2022 gala, 2024 Think Tank, and a global conference on precision medicine, where he addressed leading figures in oncology and molecular pathology. Beyond the lectern, Allen's advocacy takes multiple forms: He is currently serving as a molecular tumour board member (representing the patient’s voice) on ASCO’s TAPUR flagship clinical trial in the United States. He was the focus of an international documentary published by OncoDaily in the Fall of 2024. He is a patient mentor with Creative Destruction Lab as a member of the Cancer Patient Contribution Group, providing the patient perspective to early-stage oncology-focused companies to help them as they build and scale their businesses for next-generation clinical solutions. He has lent his voice to a television campaign for the Princess Margaret Cancer Foundation and has been featured in film trailers and various international news publications and podcasts. Allen was spotlighted on the cover of the Princess Margaret Cancer Foundation's 2023 Annual Report, acknowledging his extraordinary survivorship as a source of inspiration for cancer patients worldwide. A devoted family man, Allen attributes his remarkable survival journey to the unwavering support of his long-term girlfriend, Cynthia, and their four children. In his leisure time, he channels his competitive spirit into backgammon where he clinched the Intermediate Division title at the 2021 US Open held by the United States Backgammon Federation. Allen was born and raised in Montreal, Quebec, and now resides in Toronto, Ontario. To learn more about his life, advocacy, and professional endeavors, visit AllenChankowsky.com
Martine Elias is the CEO at Myeloma Canada, the only patient-driven, grassroots organization bringing the Canadian myeloma community together and promoting a strong, unified national voice for people living with multiple myeloma. She has been with the organisation since 2016. In addition, Martine is the Co-Chair of the Access to Treatment and Innovation Oncology Network (ACTION), a Canadian based organisation. In 2019 Martine was one of three patient representatives on the PMPRB Guideline Development Steering committee. Martine believes intentional collaboration is key to evolving the knowledge of myeloma for the betterment of patients. In February 2020 she was invited to join the International Myeloma Foundation Board of Directors and more recently she was appointed Chair to their Governance and Nominating Committee. She also serves to represent Canada on the Myeloma Patient Europe Community Advisory Board since 2019 where patient advocates address key challenges patients face in accessing diagnosis, monitoring, treatment, care and clinical trial at an international level. Martine started her career in clinical research in the pharmaceutical industry and has since dedicated her professional life to patient advocacy, empowering the patient voice, and helping patients gain access to essential medical treatments. She is passionate about ensuring that the patient voice is included in all aspects of health policy decisions. Previously, Martine was Director Access, Advocacy and Community Relations at Myeloma Canada where she developed, led and executed all advocacy strategies and programs. Prior to that Martine held roles as National Director of Community Relations at Janssen Inc., and Market Access and Health Economics team leader at GSK.
Senior Scientist and Deputy Scientific Director for Clinical Research, Ottawa Hospital Research Institute
Full Professor, Department of Medicine, and School of Epidemiology and Public Health, University of Ottawa
Endowed Chair - Ottawa Hospital Research Institute & University of Ottawa
Scientific Lead, Ontario SPOR Support Unit (OSSU)
Dr. Dean Fergusson is an international leader in evidence-based transfusion medicine and clinical trial methods. Dr. Fergusson has conceived, designed, and conducted randomized trials in transfusion medicine that have advanced knowledge and practice in defining the optimal blood product to transfuse, establishing when to administer transfusions, and evaluating transfusion alternatives. His work on clinical equipoise, post-randomization exclusions, ethical use of placebos, innovative trial design, and statistical approaches has influenced the practice and reporting of clinical trials globally. Dr. Fergusson established the Ottawa Methods Centre at the Ottawa Hospital and has led its participation in major provincial and national enterprises such as the Ontario SPOR Support Unit (OSSU) where he currently serves as Scientific Director, as well as the national CIHR-funded Accelerating Clinical Trials (ACT) Consortium. He also co-founded the BLUEPRINT translational research group which has focuses on developing novel approaches to designing and optimizing protocols for early-phase human clinical trials. Over his career, he has received over $362 million in peer reviewed research grants with over $145 million as a principal investigator. He is an ardent supporter of patient and community engagement in biomedical research and has helped establish supportive infrastructure and policy.
Michelle Audoin is an experienced and passionate patient advocate and community collaborator. She uses her living experience of cancer to shine a light on some of the disparities Black women experience when navigating a breast cancer diagnosis. Her advocacy work has also brought her to the research community where she contributes her knowledge and experiences to support clinical trials and cancer research, including roles at CCTG as the Patient Representative Committee Chair, OICR PFAC, 3CTN, All.Can Canada, Princess Margaret and Women’s College Hospital. After attending her first cancer conference, Michelle understood the importance of partnerships between both the research and patient advocate community, noting that knowledge empowers patients to not only understand cancer biology, but also to help set priorities regarding the future of cancer research and treatments. She also sees the impact these relationships have on researchers who gain insights into the experiences of people living with or supporting someone with a cancer diagnosis and how to make their work more accessible and generalizable to diverse communities. Michelle uses her background as an elementary school teacher to educate by sharing her story and experiences on podcasts, panels, and awareness campaigns. She is most proud of raising two amazing and compassionate kids who support her cancer advocacy and patient engagement work.
Dr Stuart Nicholls is Scientist in the Methodological and Implementation (MIR) program at the Ottawa Hospital Research Institute and where he leads the Office for Patient Engagement in Research Activities (OPERA). His research focuses on understanding the implementation of patient engagement in practice and improving patient engagement approaches. He is co-chair of the Accelerating Clinical Trials (ACT) Consortium Patient Engagement Committee and co-leads a working group for the World Health Organization to deliver on patient and community engagement goals set forth in the WHO Global action plan for clinical trial ecosystem strengthening (https://www.who.int/publications/i/item/B09338). He is also the purveyor of many dad jokes which are generally tolerated by colleagues and his three teenage children.
Dr. Jennifer Zelmer is the inaugural President and CEO of Healthcare Excellence Canada, the new organization formed in 2020 through the amalgamation of the Canadian Foundation for Healthcare Improvement and Canadian Patient Safety Institute to achieve safer, higher quality and more coordinated patient-partnered healthcare. Jennifer's long-standing commitment to improving healthcare quality and safety, as well as expertise in spreading and scaling innovations that deliver better outcomes, will help to create this new organization with an expanded capacity to improve healthcare for everyone in Canada. Jennifer previously joined CFHI as its President and CEO in September 2018. She has been a C.D. Howe Research Fellow for several years and is also an adjunct faculty member at the University of Victoria, as well as a member of several health-related advisory committees and boards. Previously, as President of Azimuth Health Group, Dr. Zelmer was a strategic advisor to leaders who sought to advance health and healthcare at local, national, and international levels. Before that, she held senior leadership positions with Canada Health Infoway, the International Health Terminology Standards Development Organization, and the Canadian Institute for Health Information. Jennifer served on the first (2004) Safer Healthcare Now! National Steering Committee convened by CPSI when she was at CIHI. She also served on CPSI's former Health System Innovation Advisory Committee, and more recently, Jennifer served on the National Patient Safety Consortium Steering Committee during her time at Infoway. Dr. Zelmer received her PhD and MA in economics from McMaster University and her B.Sc. in health information science from the University of Victoria.
Susan Marlin is a trusted leader in Canada’s research ethics and clinical trials community. As the President and CEO of Clinical Trials Ontario (CTO), she collaborates to strengthen the clinical trials environment while maintaining the highest ethical and quality standards. Susan was foundational in establishing CTO’s streamlined research ethics review system to enable a single review for multi-site clinical trials and health research studies in Ontario. Now widely adopted, the system has more than 11,000 users, 160 participating sites, 300 pharmaceutical and medical device companies, and 20 qualified research ethics boards. Building on her record of uniting partners to streamline clinical trials, Susan is advancing key projects across Canada. She is the nominated principal investigator for the Canada-wide CHEER project, supported by the Canadian Institutes of Health Research (CIHR) to streamline ethics reviews for child health research. She is also the nominated principal applicant for the CanReview collaboration to establish a pan-Canadian single research ethics review system, supported by the CIHR-funded Accelerating Clinical Trials (ACT) Consortium. Prior to CTO, Susan served as the Associate Vice-Principal at Queen’s University, working with the Canadian Cancer Trials Group to coordinate clinical trials and lead the development and implementation of the Ethics and Regulatory Office. Susan has served as President of the Canadian Association of Research Ethics Boards, and as a member of the CIHR Research Integrity Committee, the Ontario Cancer Research Ethics Board, and the Tri-Agency Panel on the Responsible Conduct of Research. Susan sits on the Board of Directors and Executive Committee of Life Sciences Ontario. She serves on the Operations Committee and is co-chair of the Ethics Committee for the ACT Consortium. She is on the Management Team for the Ontario Strategy for Patient-Oriented Research Support Unit, and she is an Adjunct Lecturer at Queen’s University in Kingston, Ontario.
Brian Canter is an Assistant Research Director on the Biomedical Innovation team working on policy solutions to improve development, regulatory review, and evidence generation for broadening access and availability to medical products. He manages one of the Biomedical Innovation team's cooperative agreements with the U.S. Food and Drug Administration (FDA). Brian's portfolio of work spans several key areas within the biomedical innovation space. As the lead researcher on regulatory considerations to enable greater competition for biologics, he has evaluated the value of the interchangeability designation and derived strategies to foster future biosimilar development for cell and gene therapies. Supporting the Institute's thought leadership to modernize clinical trials, Brian guides the policy work for the Coalition for Advancing Clinical Trials at the Point of Care. Brian has also managed several projects within the Institute's regulatory science work, including public meetings convened with FDA to advance clinical trial innovation and premarket safety analytics. In addition to biomedical innovation, Brian has done extensive work within the Institute's 21st Century Public Health and Population Health portfolio. He oversaw a project focused on addressing the burden of respiratory viruses through reduction of disease transmission. During the COVID-19 pandemic, Brian led the Institute's work to maximize adoption of therapeutics, with a focus on Test-to-Treat pathways. Prior to joining Duke-Margolis, Brian completed a PhD in Biomedical Sciences with a focus in Biomedical Engineering from Rutgers University. His thesis research focused on utilizing radiation therapy systemically to treat metastatic breast cancer that spread to bone. Brian also graduated with a Bachelor of Science in Biomedical Engineering from Tufts University.
DON HUSEREAU is an Adjunct Professor of Medicine at The University of Ottawa. He does freelance health care research, and works with private and public sector life sciences organizations to help them understand the value of health technology and its implications for health and innovation policy.
Dr. O'Callaghan received his Doctorate in Veterinary Medicine and MSc and PhD degrees in Epidemiology from the University of Guelph, based on work conducted on the epidemiology of infections of livestock while a Medical Research Council of Canada Fellow at the International Livestock Research Institute in Nairobi, Kenya. He continued his research and training in infectious diseases epidemiology as a Wellcome Trust Senior Research Fellow at the University of Warwick. In 2001 he joined the Canadian Cancer Trials Group where he continues to oversee the Gastrointestinal and Brain Site Committees as Senior Investigator. He is also a Professor in the Department of Public Health Sciences. His research interests are diverse and include clinical trials design and methodology and infectious disease epidemiology.
Dr. Laupacis is Consulting Editor of CMAJ (Canadian Medical Association Journal) and a specialist in internal medicine; he also practiced palliative care. He has published over 370 peer-reviewed articles covering a variety of topics in clinical epidemiology, health services research, health technology assessment and health policy. He was founder of the web site www.healthydebate.ca. Dr. Laupacis is Professor Emeritus at the University of Toronto. He has held faculty appointments at the University of Western Ontario (1986-1991), University of Ottawa (1991-2000) and the University of Toronto (2000-present). He has served as Director of the Clinical Epidemiology Unit, University of Ottawa (1991-2000); CEO of ICES (formerly the Institute for Clinical Evaluative Sciences) (2000-2006) and Executive Director of the Li ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto (2006-2018). He has served on numerous academic and non-academic committees, including serving on the Boards of Alberta Health Services, Cancer Care Ontario and Health Quality Ontario. He is currently a board member of the Waterloo Regional Health Network. Dr. Laupacis has been awarded the Justice Emmett Hall Laureate (2010), the Health Services Research Advancement Award from the Canadian Health Services Research Foundation (2011), the CIHR’s Barer-Flood Prize in Health Services and Policy Research (2013), the University of Toronto President’s Impact Award (2018), the Carolyn Tuohy Impact on Public Policy Award, University of Toronto (2018) and the FNG Starr Award of the Canadian Medical Association (2018). He is a Fellow of the Royal Society of Canada (2015) and Officer of the Order of Canada (2022).
Michelle is an experienced lawyer, public affairs professional and leader in both the corporate and not-for-profit sectors. Over the past 20 years, Michelle has provided strategic counsel and leadership to a wide array of organizations in the health and life sciences sector, including health charities, health research organizations, hospitals, pan-Canadian government-funded health organizations, and pharmaceutical and health technology companies. Having led the development of many national communications, stakeholder engagement and government relations strategies and campaigns, she is best known as a skilled and strategic advocate who has secured significant policy and funding commitments at the federal level. Michelle previous leadership roles include General Manager at Hill + Knowlton Strategies, one of Canada’s largest public affairs agencies, and Vice President at the Mental Health Commission of Canada.
Enrique Sanz Garcia is a medical oncologist and staff physician at the Princess Margaret Cancer Centre, with a clinical focus on head and neck, and gastrointestinal cancers. He was trained in Madrid, Spain, and completed his medical oncology residency at the Vall d'Hebron Oncology Institute in Barcelona. He also completed his PhD in Medicine, focusing on liquid biopsy in colorectal cancer, at the Autonomous University of Barcelona. In 2020, he moved to Toronto for a 3-year fellowship in drug development and the head and neck program. Upon completion, he was appointed as a staff physician at UHN. His main areas of research include precision medicine based on molecular profiling, liquid biopsy, and early-onset cancers of the gastrointestinal tract. He serves also as the scientific co-lead for the Marathon of Hope Cancer Centre Network program at Princess Margaret, chairs the molecular tumor board for this initiative, and co-chairs the working group for the development of a prospective study to bring precision medicine to cancer patients across Canada.
28-10-2025 09:00 am
toOpening Remarks and Introductions: Barry Stein, President & CEO, Colorectal Cancer Canada (CCC) and Anne Marie Wright, President of Elements Strategy.
Anne Marie Wright
Barry Stein28-10-2025 09:10 am
to- What needs to evolve/change and how. (every cancer patient has access to the best care)
- Call to Action. Learning from Patients. (unraveling the miracle)
Speaker: Dr. Rebecca Auer, CEO & Scientific Director, Ottawa Hospital Research Institute (OHRI) Executive Vice-President Research and Innovation, The Ottawa Hospital
Rebecca Auer28-10-2025 09:40 am
to- Where are we today? What does it mean to embed trials into care?
- Why is this critically important for equitable access to care? Discuss trial differences and “language” – pragmatic versus interventional
Session Chair: Dr. Rebecca Auer, CEO & Scientific Director, OHRI
Panel: Michelle McLean, President & CEO, HealthCareCAN
Jennifer Zelmer, President & CEO, Heathcare Excellence Canada
Dr. Laupacis, Consulting Editor of CMAJ (Canadian Medical Association Journal), specialist in internal medicine
Rebecca Auer
Dr. Jennifer Zelmer
Michelle McLean
Dr. Laupacis28-10-2025 11:00 am
to28-10-2025 11:30 am
to- Hope through access to innovation; the benefits of designing trials with patients and patient groups; sharing challenges and potential solutions; personal experiences. Focus of this session is “the why”
Session Chair: Barry Stein, President & CEO, CCC
Panel : Michelle Audoin, CCTG Patient Representative, patient advocate
Allen Chankowsky, Acclaimed author, sought-after international speaker, and patient
Martine Elias, Chief Executive Officer, Myeloma Canada
Allen Chankowsky
Martine Elias
Barry Stein
Michelle Audoin28-10-2025 12:30 pm
to28-10-2025 01:30 pm
toThree speakers plus panel interaction
Dr. Enrique Sanz Garcia28-10-2025 02:45 pm
to28-10-2025 03:00 pm
to- Overview with key focus on how we can build stronger health system capacity and infrastructure to embed research into care (how this recommendation is moving forward)
Panel: Dr. Rebecca Auer, CEO & Scientific Director, OHRI
Dr. Chris O’Callaghan, Canadian Cancer Trials Group Senior Investigator
Dr. Stuart Edmonds, Executive VP, Mission, Research and Advocacy, Canadian Cancer Society
Stuart Edmonds
Rebecca Auer
Dr. Chris O’Callaghan28-10-2025 04:00 pm
toIn small groups, conference participants summarize key learning, insights and potential actions for change.
28-10-2025 05:00 pm
to29-10-2025 09:00 am
to
Barry Stein
Anne Marie Wright29-10-2025 09:10 am
to- How Australia streamlined trials, increased access, and empowered patients and clinicians (the business case for change)
- Creation of a National infrastructure for embedded trials (sets the stage for what needs to happen and how)
Presentation with Q&A: The Australian Framework continued: Creation of a National Infrastructure for Embedded Trials
Speaker: Kurt Lackovic, CEO, Cancer Trials Australia
Kurt Lackovic29-10-2025 10:15 am
to- Focus: Cultural Change, Training and Ethics
Panel: Susan Marlin, President & CEO, Clinical Trials Ontario
Rebecca Barnes, Executive Director, N2
Dr. Stuart Nicolls, Scientist, Methodological and Implementation Research, OHRI
Rebecca Barnes
Dr. Stuart Nicolls
Susan Marlin29-10-2025 11:15 am
to29-10-2025 11:35 am
toOperations, Logistics, Data Collection, Regulatory
Panel: Dr. Sébastien Perreault, Director of pediatric neurology program, CHU Sainte-Justine
Dr. Sébastien Perreault
Don Husereau29-10-2025 12:35 pm
to29-10-2025 01:15 pm
to- Real-world evidence (RWE) is transforming oncology by uniting research and care. This session explores how modernizing RWE—through data integration, pragmatic trials, and patient engagement—can accelerate innovation, close evidence gaps, and improve outcomes.
- Stakeholder co-ordination and participation
Speaker: Dr. Brian Cantor, Assistant Research Director at the Duke-Margolis Institute for Health Policy
Dr. Brian Canter29-10-2025 02:15 pm
to- Key stakeholder from REaCT program shares what needs to be done in the Canadian context – short, medium, long term
- Followed by an Open Forum for audience interaction. Identify tangible actions and high-level plan to move forward
Speaker: Dr. Dean Fergusson, Deputy Scientific Director & Senior Scientist, OHRI
Dr. Dean Fergusson29-10-2025 03:15 pm
to
Barry SteinUnlocking faster innovation for better access, outcomes and hope
Download the PDF and send us an email to learn more about sponsorship opportunities.
Holiday Inn & Suites Montreal Centre - Ville Ouest
1390, boulevard René-Lévesque Ouest
Montreal, Quebec H3G 0E3, Canada
When you make a gift to Colorectal Cancer Canada, you’re doing more than extending a helping hand – you’re directly supporting patients and their loved ones across the country and investing in the future of cancer research and advocacy.
DONATE